Now, we further explore the underlying mechanisms of tumor-targeted costimulation using a novel bispecific antibody that co-engages CD28 with the tumor-associated antigen B7-H3, assessing its activity in combination with endogenous and exogenous sources of Signal 1, and with immune checkpoint inhibition. The gene discussed is CD28; the disease is neoplasm.